Hemab Therapeutics Holdings, Inc.
(Incorporated in Delaware) We are a clinical-stage biotech company focused on developing subcutaneous treatments for rare blood coagulation disorders. Our lead therapeutic candidate, sutacimig – also known as HMB-001, has completed Phase 2 trials and it’s ready for Phase 3 for the treatment of Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency. Our therapeutic […]
April 11, 2026 Read More